# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: )Primary Examiner:
Filed: **Herewith** )Mr.Francis J.
)Jawarski

In re Application of Dr. William M. Hammesfahr
For: ...Method of Diagnosis and Treatment and
Related Compositions and Apparatus
Priority: 09/101,934 Filed: 07/13/98;
PCT/US96/27745; Provisional 60/010881
Attorney Docket: 003BUS )703 308 3061
) Art Unit 3737
)Fax: 703 305 3590

Response Due: Not Applicable

Assistant Commissioner for Patents
Box US Washington, DC 20231
Sir:

## PRELIMINARY AMENDMENT

Applicant's Attorney certifies that this Amendment has been filed in the United States Patent and Trademark Office on 23 April 2001as Express Mail Document E1953565410US

.

In response to the Requirement for Restriction by Primary Examiner Jaworski in the parent Application, consideration of the following nonelected claims in this Divisional Application filed herewith is requested:

IN THE SPECIFICATION

Please insert the following before the period in the first sentence below the Title: --and of USSN 09/101,934 filed 07/13/1998 now U.S. Patent _____--

IN THE CLAIMS

Please cancel the prior claims and substitute the following in this Divisional Application:

32. Vasodilator delivery systems specially adapted to deliver about 5 to 25%of conventional dosage of vasodilators and marked with the appropriate DRG and/or ICD disease codes and/or instructions for titrating or tapering their use, to facilitate their proper application for treatment of diseases involving vasospasm.

33. A delivery system according to Claim 32 adapted for transdermal delivery.

34. A delivery system according to Claim 32 adapted for delivery of about 0.02 to 20 milligrams per day (Nitroglycerin equivalent) of vasodilator.

35. A delivery system according to Claim 32 adapted for delivery of about 0.02 to 20 milligrams per day (Nitroglycerin equivalent) of a vasodilator selected from the group comprising
Nitroglycerin in pill, patch, ointment, cream, inhaler, spray and other forms, Nitroglycerin equivalents and substitutes, comprising p.o. clonidine, Dynacirc (isradipine), hydrazine, nifedipine, and/or other medicines selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

36. A method according to Claim 21 wherein the disease is selected from the group consisting of fibromyalgia, gastric disorders and other systemic disorders, psychosis, other psychiatric disease, attention deficit disorder and systemic disorders, comprising vasospasm as a component.

37. A method according to Claim 21 wherein the disease is selected from the group consisting of systemic disorders comprising vasospasm as a component.

38. A titration system for diagnosing and treating a disease caused at least partially by insufficient cerebral perfusion, comprising in combination: operating a flow device to test for
vasospasm, applying a dosage device which administers a vasospasm-reducing dosage of a medicine selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which reduce pulmonary capillary wedge pressure, reoperating said flow device for testing over time and adjusting said dosage device to titrate said dosage to minimize occurrence and severity of said indications of vasospasm.

REMARKS

Any (small entity) charges required for the prosecution of this application should henceforth be charged to USPTO Deposit Account 20-0336 of Technology Licensing Co. LLC.

Please advise if anything further is required at this time.

Respectfully submitted,

Richard Coale Willson, Jr.
Attorney for Applicant
USPTO Registration No. 22,080
Technology Licensing Co LLC
3205 Harvest Moon Dr. Ste 200

Palm Harbor FL 34683-2127
727 781 0089
*Fax: 727 785 8435*
Email:rwillso@aol.com

003BUSPreliminaryAmendment20010423.doc